Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

49 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
CD34+CD38-CD123+ Leukemic Stem Cell Frequency Predicts Outcome in Older Acute Myeloid Leukemia Patients Treated by Intensive Chemotherapy but Not Hypomethylating Agents.
Vergez F, Nicolau-Travers ML, Bertoli S, Rieu JB, Tavitian S, Bories P, Luquet I, Mas V, Largeaud L, Sarry A, Huguet F, Delabesse E, Bérard E, Récher C. Vergez F, et al. Among authors: largeaud l. Cancers (Basel). 2020 May 6;12(5):1174. doi: 10.3390/cancers12051174. Cancers (Basel). 2020. PMID: 32384744 Free PMC article.
More than ten percent of relapses occur after five years in AML patients with NPM1 mutation.
Bertoli S, Tavitian S, Bérard E, Mansat-De Mas V, Largeaud L, Gadaud N, Rieu JB, Vergez F, Luquet I, Huguet F, Sarry A, Delabesse E, Récher C. Bertoli S, et al. Among authors: largeaud l. Leuk Lymphoma. 2020 May;61(5):1226-1229. doi: 10.1080/10428194.2019.1706733. Epub 2020 Feb 5. Leuk Lymphoma. 2020. PMID: 32022605 No abstract available.
Outcome of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia Before Second-Generation FLT3 Tyrosine Kinase Inhibitors: A Toulouse-Bordeaux DATAML Registry Study.
Bertoli S, Dumas PY, Bérard E, Largeaud L, Bidet A, Delabesse E, Tavitian S, Gadaud N, Leguay T, Leroy H, Rieu JB, Vial JP, Vergez F, Lechevalier N, Luquet I, Klein E, Sarry A, Grande AC, Récher C, Pigneux A. Bertoli S, et al. Among authors: largeaud l. Cancers (Basel). 2020 Mar 25;12(4):773. doi: 10.3390/cancers12040773. Cancers (Basel). 2020. PMID: 32218221 Free PMC article.
Dactinomycin in acute myeloid leukemia with NPM1 mutations.
Beziat G, Tavitian S, Bertoli S, Huguet F, Largeaud L, Luquet I, Vergez F, Rieu JB, Bories P, Delabesse E, Récher C. Beziat G, et al. Among authors: largeaud l. Eur J Haematol. 2020 Sep;105(3):302-307. doi: 10.1111/ejh.13438. Epub 2020 May 25. Eur J Haematol. 2020. PMID: 32452083
Dendrogenin A synergizes with Cytarabine to Kill Acute Myeloid Leukemia Cells In Vitro and In Vivo.
Serhan N, Mouchel PL, Medina P, Segala G, Mougel A, Saland E, Rives A, Lamaziere A, Despres G, Sarry JE, Larrue C, Vergez F, Largeaud L, Record M, Récher C, Silvente-Poirot S, Poirot M. Serhan N, et al. Among authors: largeaud l. Cancers (Basel). 2020 Jun 29;12(7):1725. doi: 10.3390/cancers12071725. Cancers (Basel). 2020. PMID: 32610562 Free PMC article.
Real-World Outcomes of Patients with Refractory or Relapsed FLT3-ITD Acute Myeloid Leukemia: A Toulouse-Bordeaux DATAML Registry Study.
Dumas PY, Bertoli S, Bérard E, Largeaud L, Bidet A, Delabesse E, Leguay T, Leroy H, Gadaud N, Rieu JB, Vial JP, Vergez F, Lechevalier N, Luquet I, Klein E, Sarry A, de Grande AC, Pigneux A, Récher C. Dumas PY, et al. Among authors: largeaud l. Cancers (Basel). 2020 Jul 24;12(8):2044. doi: 10.3390/cancers12082044. Cancers (Basel). 2020. PMID: 32722211 Free PMC article.
49 results